TiGenix’s second stab at an IPO bags $36M for late-stage stem cell plans
Belgian biotech TiGenix has finally pulled off an IPO on Nasdaq. The stem cell player had to retrieve an offering that had been …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
